Current biomarkers (including cerebrospinal fluid (CSF) measures of tau and TDP-43) do not accurately identify the underlying proteinopathy in vivo in FTD, and therefore novel measures are being investigated,1 including assays utilising blood samples which are less invasive than CSF. The gene discussed is TARDBP; the disease is frontotemporal dementia.